GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia

Company Announcement

  • Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of 9.3 months compared to chlorambucil alone
  • No unexpected safety findings

COPENHAGEN, Denmark and LONDON, May 29, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) and GlaxoSmithKline plc (GSK) announced today that their Phase III study of ARZERRA(R) (ofatumumab) in combination with chlorambucil versus chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL) met its primary endpoint of progression free survival (PFS) as assessed by an Independent Review Committee (IRC).

A total of 447 patients were enrolled in the study. A 9.3 month improvement in the time a patient lived without worsening of their disease (median PFS) was seen in patients randomized to ofatumumab and chlorambucil compared to patients randomized to chlorambucil alone (22.4 months vs. 13.1 months; Hazard Ratio 0.57; p<0.001).

There were no unexpected safety findings. The most common (>=1%) serious adverse events as reported by the investigator within 60 days of last treatment were neutropenia [including febrile neutropenia] (5%), anaemia (4%), pneumonia (4%), and pyrexia (2%). Infusion reactions were mild to moderate in severity with 3% of infusion reactions reported as serious.

"We are delighted with the positive results from this trial which we believe may lead to ofatumumab plus chlorambucil as an additional treatment option for the care of patients with CLL," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "We look forward to submitting the study results, including secondary endpoints, to the International Workshop on CLL (iwCLL) in Cologne, Germany this September."

"As the aim of treating CLL, particularly in the frontline setting, is to maximize progression free survival while minimizing side effects, we are therefore encouraged by these promising results," said Dr. Kathy Rouan, Vice President BioPharmaceutical Development, GlaxoSmithKline. "We are planning regulatory submissions in the EU, US, and other regions in the coming months."

About the study

This Phase III study (NCT00748189) included patients with previously untreated CLL considered inappropriate for fludarabine-based therapy. Patients in the study were randomized 1:1 to treatment with up to twelve cycles of ofatumumab in combination with chlorambucil or up to twelve cycles of chlorambucil alone. The primary endpoint of the study was PFS according to the International Workshop for Chronic Lymphocytic Leukaemia (IWCLL) updated 2008 National Cancer Institute-sponsored Working Group (NCIWG) guidelines, using an independent endpoints review committee.

About chronic lymphocytic leukemia

CLL is the most common form of leukemia in adults. Based on estimates by the American Cancer Society, CLL will account for more than 15,680 new cases and more than 4,580 deaths in the United States of America alone in 2013. At present, no curative chemotherapy is available.

About ARZERRA (ofatumumab)

Ofatumumab is not approved or licensed anywhere in the world for use in patients who have not received treatment for CLL. For Full US Prescribing Information, please visit: and visit for the EU SPC for the approved indication.

Ofatumumab is a human monoclonal antibody which targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops (Teeling et al 2006). Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

About GSK

GSK is one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For further information please visit

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit

GSK Contact:

UK Media enquiries:
David Mawdsley +44 (0) 20 8047 5502 (London)
David Daley +44 (0) 20 8047 5502 (London)
Catherine Hartley +44 (0) 20 8047 5502 (London)

US Media enquiries:
Bernadette King +1 215 751 3632 (Philadelphia)
Anna Padula +1 215 751 4271 (Philadelphia)
Melinda Stubbee +1 919 483 2510 (North Carolina)
Karen Collins +1 919 483 2527 (North Carolina)
Stephen Rea +1 215 751 4394 (Philadelphia)

Analyst/Investor enquiries:
Ziba Shamsi +44 (0) 20 8047 3289 (London)
Lucy Budd +44 (0) 20 8047 2248 (London)
Tom Curry +1 215 751 5419 (Philadelphia)
Gary Davies +44 (0) 20 8047 5503 (London)
James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Genmab Contact:

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E:

Cautionary Statement Regarding Forward Looking-Statements for GSK

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

Forward Looking Statement for Genmab

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); DuoBody(R), HexaBodyTM and UniBody(R). Arzerra(R) is a trademark of GlaxoSmithKline.

Company Announcement no. 24
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K

Source:Genmab A/S